Regnum CorpOTC Pink - Current Information:RGMP
- LAST PRICE0.1200
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots---/ ---
- Ask / Lots---/ ---
- Open / Previous Close0.0000 / 0.1200
- Day Range---
- 52 Week Range
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Regnum Corp | 2.8M | -3.0x | --- |
CNS Pharmaceuticals Inc | 2.9M | -6.0x | --- |
ContraFect Corp | 2.9M | 0.0x | --- |
Proteo Inc | 3.0M | 0.0x | --- |
NovAccess Global Inc | 3.0M | -1.5x | --- |
Pharmagreen Biotech Inc | 3.1M | -2.8x | --- |
Company Information
Regnum Corp. is a biopharmaceutical company. The Company is focused on late-stage commercial and clinical development programs. The Company is engaged in developing and commercializing therapeutics that treat rare and infectious diseases, specifically in populations that are neglected or face adherence challenges due to inconvenient dosing or delivery system, tolerability, or cost and accessibility of available therapeutic options. The Company's primary asset is the commercial rights to leronlimab (PRO 140) in all human immunodeficiency virus (HIV) indications within the United States. leronlimab is used as a platform drug for a variety of HIV indications. The target of leronlimab is the immunologic receptor C-C chemokine receptor type 5 (CCR5). Leronlimab prevents certain strains of HIV from using the CCR5 receptor as an entry gateway for healthy cells.
Contact Information
- Headquarters
- 600 THIRD AVENUE, 10THNEW YORK, NY, United States 10016
- Phone
- 917-647-1498
- Fax
- ---
Executives
- President, Chief Executive Officer, Director
- Anne Kirby
- Chief Financial Officer, Treasurer
- Robert Stubblefield
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $2.8M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 23.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-0.04 |
Book Value | $-0.02 |
P/E Ratio | -3.0x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
